公司概覽
業務類別 Biotechnology
業務概覽 Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
公司地址 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
電話號碼 +1 650 624-3000
傳真號碼 +1 650 624-3010
公司網頁 https://www.cytokinetics.com
員工數量 673
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Jeffrey J. Hessekiel Executive Vice President, Chief Legal and Administrative Officer -- 14/11/2025
Dr. Fady Ibraham Malik, M.D.,PhD Executive Vice President, Research and Development 美元 609.46K 10/04/2025
Mr. Robert I. Blum Director, President and Chief Executive Officer 美元 825.55K 26/02/2026
Mr. Sung H. Lee Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 550.00K 26/02/2026
Mr. Andrew M. Callos Executive Vice President and Chief Commercial Officer 美元 562.91K 10/04/2025
 
董事會成員
董事會 職務 更新日期
Dr. Robert A. Harrington, M.D. Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. John T. Henderson, M.B. Chairman of the Board 26/02/2026
Ms. Nancy J. Wysenski Independent Director 26/02/2026
Dr. Edward M. Kaye, M.D. Independent Director 26/02/2026
Dr. Wendell D. Wierenga,PhD Independent Director 26/02/2026
Mr. Robert I. Blum Director, President and Chief Executive Officer 26/02/2026
Ms. B. Lynne Parshall, Esq.,J.D. Independent Director 26/02/2026
Ms. Muna Bhanji, Ph. Independent Director 26/02/2026
Mr. Robert E. Landry Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:31)
代號 名稱 佔比% 持有日期
IVOVVanguard S&P Mid-Cap 400 Value ETF0.04%31/01/2026
JMEEJPMorgan Small & Mid Cap Enh Eq ETF0.03%27/02/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.03%27/02/2026
ISCGiShares Morningstar Small-Cap Growth ETF0.03%28/02/2026
TCALT. Rowe Price Cap Apprec Prm Inc ETF0.03%28/02/2026
FFSMFidelity Fundamental Small-Mid Cap ETF0.03%31/01/2026
ONEQFidelity Nasdaq Composite ETF0.03%27/02/2026
JHMMJHancock Multifactor Mid Cap ETF0.03%27/02/2026
IWViShares Russell 3000 ETF0.02%28/02/2026
ESGVVanguard ESG US Stock ETF0.02%31/01/2026
JHSCJHancock Multifactor Small Cap ETF0.02%27/02/2026
SPTMState StreetSPDRPortS&P1500CompStkMktETF0.02%27/02/2026
GSCGoldman Sachs Small Cap Equity ETF0.02%27/02/2026
BKMCBNY Mellon US Mid Cap Core Equity ETF0.02%28/02/2026
NBCRNeuberger Core Equity ETF0.01%28/02/2026
PTMCPacer Trendpilot™ US Mid Cap ETF0.01%27/02/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF0.01%26/02/2026
FMEDFidelity Disruptive Medicine ETF0.01%27/02/2026
VTWGVanguard Russell 2000 Growth ETF0.01%31/01/2026
VTHRVanguard Russell 3000 ETF0.01%31/01/2026
  1    2   3    4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.